Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

Add IDRA Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 8/15/2018 5:16:54 PM - Followers: 139 - Board type: Free - Posts Today: 0

The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.

In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.

IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.

The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.




Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA News: Current Report Filing (8-k) 01/09/2019 04:08:19 PM
IDRA News: Current Report Filing (8-k) 01/07/2019 07:47:17 AM
IDRA News: Statement of Changes in Beneficial Ownership (4) 01/04/2019 04:54:32 PM
IDRA News: Idera Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference 01/04/2019 07:30:00 AM
IDRA News: Statement of Changes in Beneficial Ownership (4) 01/03/2019 04:44:38 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#3253   * * $IDRA Video Chart 08-15-18 * * ClayTrader 08/15/18 05:16:54 PM
#3252   * * $IDRA Video Chart 08-14-18 * * ClayTrader 08/14/18 05:28:50 PM
#3251   * * $IDRA Video Chart 08-09-18 * * ClayTrader 08/09/18 05:37:40 PM
#3250   This is a Great time for News with dwh 07/29/18 09:05:16 PM
#3249   Guess everyone saw the AH 1-8 r/s that Citrati 07/27/18 11:19:53 PM
#3248   Citrati, what do you think of IDRA at LGviolet 07/24/18 03:53:34 PM
#3247   If anyone still cares. Citrati 07/24/18 12:12:23 PM
#3246   * * $IDRA Video Chart 07-18-18 * * ClayTrader 07/18/18 05:31:28 PM
#3245   i was wrong...BIG TROUBLE here noretreat 07/18/18 12:32:37 PM
#3244   Anyone know what is happening here? snoyzflake 07/18/18 12:04:22 PM
#3243   News out Wolf91 07/16/18 07:06:32 AM
#3242   * * $IDRA Video Chart 07-13-18 * * ClayTrader 07/13/18 04:57:00 PM
#3241   * * $IDRA Video Chart 07-11-18 * * ClayTrader 07/11/18 05:14:48 PM
#3240   Trouble here noretreat 07/11/18 02:40:31 PM
#3239   Go for Aveo and ipix check them out youssef 07/11/18 02:22:34 PM
#3238   Hitting some good resistance, looking to add more Wolf91 07/11/18 01:21:36 PM
#3237   Yea it'll recover after the short term fear Wolf91 07/11/18 10:48:53 AM
#3236   I m holding my shares and I m youssef 07/11/18 10:43:24 AM
#3235   Yea, merger or no merger, idra wins out. Wolf91 07/11/18 09:03:06 AM
#3234   The merger didn t go thru idra got youssef 07/10/18 06:37:00 PM
#3233   Yea that's what I was reading as well, Wolf91 07/10/18 01:42:01 PM
#3232   Then we should hear if went thru or youssef 07/10/18 01:40:20 PM
#3231   Correct, it happens today Wolf91 07/10/18 01:25:45 PM
#3230   Tomorrow is the result for the merger vote youssef 07/09/18 02:13:58 PM
#3229   $IDRA Looks like a r/s coming. https://www.sec.gov/Archives/edgar/data/861838/ outnabout 07/01/18 04:43:31 PM
#3228   IDRA grabbing 1.30 I see like 5 bottoms MONSTAMONEYMOVA 06/25/18 03:05:01 PM
#3227   Still hanging around. Bid sitting right now with Citrati 06/22/18 02:53:25 PM
#3226   It wasn’t a big deal this trial , youssef 06/12/18 11:05:13 PM
#3225   * * $IDRA Video Chart 06-12-18 * * ClayTrader 06/12/18 05:25:33 PM
#3224   That's not one I have followed. Citrati 06/12/18 09:17:40 AM
#3223   haven't held any for some time. what noretreat 06/12/18 09:11:16 AM
#3222   Will have to wait for the dust to Citrati 06/12/18 09:00:58 AM
#3221   stock is not taking that big of a noretreat 06/12/18 08:24:46 AM
#3220   And, there is $2 again. Citrati 05/30/18 10:23:29 AM
#3219   I concur. I feel we should be a Phantom Lord 05/25/18 12:47:32 PM
#3218   Thanks. This looks like a decent spot scottsmith 05/25/18 12:36:15 PM
#3217   ir.iderapharma.com/static-files/0d9f6afa-aad4-4478-80b4-5f34bdfae9f4 [ Phantom Lord 05/25/18 12:00:17 PM
#3216   Baker’s that confident that they doubled shares from scottsmith 05/25/18 11:28:28 AM
#3215   Would be nice to see a little more Phantom Lord 05/24/18 11:53:45 AM
#3214   Idera Pharmaceuticals (NASDAQ:IDRA) is up 4% premarket on Citrati 05/24/18 11:24:40 AM
#3213   Nice synopsis 'kid2'. No disagreement from me Citrati 05/20/18 06:10:34 PM
#3212   I say it runs. Too much momentum building. kld2 05/20/18 05:48:32 PM
#3211   See if it can hold and build now Citrati 05/20/18 05:28:17 PM
#3210   Yep, it is why I love this stock. Citrati 05/16/18 06:26:02 PM
#3209   Nice Back over 2$ :-D $idra Cbdpotential 05/16/18 02:03:48 PM
#3208   I will put it on my to do list. terry hallinan 04/27/18 10:31:10 AM
#3207   Check ipix , the company is in my youssef 04/27/18 07:18:34 AM
#3206   Idera Pharmaceuticals, Inc. (Idera) (NASDAQ:IDRA), a clinical-stage biopharma terry hallinan 04/27/18 01:29:55 AM
#3205   Idera Pharmaceuticals, Inc. (Idera) (NASDAQ:IDRA), a clinical-stage biopharma terry hallinan 04/27/18 01:29:53 AM
#3204   Check idra news for asco presentation youssef 04/26/18 07:29:54 PM